Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Research

Th2-polarisation of cellular immune memory to neonatal pertussis vaccination

Current infant vaccination against pertussis in North America and Australia requires three doses of vaccines including diphtheria, tetanus and acellular...

News & Events

New study examines vacccine to prevent cervical cancer

The Telethon Institute for Child Health Research today announced a new study investigating a vaccine to prevent infection of Human Papilloma Virus (HPV).

News & Events

Extra whooping cough shots to protect bubs

An extra whooping cough vaccination for babies comes as a result of work by researchers at the Wesfarmers Centre of Vaccines and Infectious Diseases.

News & Events

Free vaccination public seminar

Immunisation plays an important role in preventing disease within our community. Join us at a FREE public seminar on vaccinations.

News & Events

Trans Tasman action to fast track rheumatic fever vaccine

Prime Ministers of Australia and New Zealand have agreed to provide $3M to help fast-track the development of a vaccine against rheumatic fever.

News & Events

State Immunisation Strategy Released

The State Government has launched a new strategy for improving immunisation rates among WA children, to prevent outbreaks of diseases like measles & meningitis

Research

Immunogenicity, Reactogenicity, and Safety of a Pentavalent Meningococcal ABCWY Vaccine in Adolescents and Young Adults who had Previously Received a Meningococcal ACWY Vaccine

A MenABCWY vaccine containing 4CMenB and MenACWY-CRM vaccine components has been developed to protect against the 5 meningococcal serogroups that cause most invasive disease cases.

Research

Short term safety profile of respiratory syncytial virus vaccine in adults aged ≥ 60 years in Australia

Australia's active vaccine safety surveillance system AusVaxSafety monitors a number of vaccines, including Arexvy, by reporting on solicited adverse events following immunisation (AEFI) through an online survey sent to vaccinees 3 days post-vaccination as previously described.3 Here we report on survey responses from adults aged ≥60 years receiving Arexvy at primary healthcare practices or pharmacies, who responded to the survey by day 7 post-vaccination.

Research

Evaluation of Pediatric HIV Postexposure Prophylaxis Guideline Following Child Sexual Assault in Western Australia

HIV postexposure prophylaxis (PEP) following child sexual assault (CSA) is recommended in select cases. High rates of poor adherence to PEP are reported. We evaluated adherence to the recommended management of children following CSA at the tertiary pediatric facility in Western Australia and compared our approach with international guidelines.